Announcement
14 Oct 2022
In October 2022, the Norwegian authorities introduced an export notification on Tixagevimab–cilgavimab, Sotrovimab, and Casirivimab-imdevimab associated with an outbreak of COVID-19.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
14 Oct 2022
Revocation date:
01 Jul 2023
Updated: 14 Oct 2022
Export licensing requirement
On 14 October 2022, the Norwegian Medicines Agency introduced an export notification requirement on the following drugs: Tixagevimab–cilgavimab, Sotrovimab, and Casirivimab-imdevimab.
According to the...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.